Tham khảo Cerivastatin

  1. ↑ “International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 36” (PDF). World Health Organization. 1996. tr. 142. Truy cập ngày 29 tháng 11 năm 2016.
  2. ↑ Furberg CD, Pitt B (2001). “Withdrawal of cerivastatin from the world market”. Curr Control Trials Cardiovasc Med. 2 (5): 205–207. doi:10.1186/cvm-2-5-205. PMC 59524. PMID 11806796.
  3. ↑ Psaty BM, Furberg CD, Ray WA, Weiss NS (2004). “Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis”. JAMA. 292 (21): 2622–31. doi:10.1001/jama.292.21.2622. PMID 15572720.
  4. ↑ Zeitlinger M, Müller M (2003). “[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis]”. Wien Med Wochenschr (bằng tiếng Đức). 153 (11–12): 250–4. doi:10.1046/j.1563-258X.2003.03029.x. PMID 12879633.Quản lý CS1: ngôn ngữ không rõ (liên kết)
  5. ↑ Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R (2005). “[Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]”. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku (bằng tiếng Nhật) (123): 41–5. PMID 16541751.Quản lý CS1: ngôn ngữ không rõ (liên kết)
  6. 1 2 3 “Cerivastatin”.
  7. 1 2 , 7.Mück W. 2000. Clinical Pharmacokinetics of Cerivastatin. Clinical Pharmacokinetics 39(2):99-116
  8. ↑ , 8. Kuhlmann J, Mück W, Bischoff H, von Keutz H, Llewellyn M (1998). “Cerivastatin (BAY w 6228): A Novel HMG-CoA Reductase Inhibitor”. Cardiovascular Drug Reviews, 16 (3): 236-263
  9. ↑ , 10. Endo A (1992). “The discovery and development of HMG-CoA reductase inhibitors”. Journal of Lipid Research, 33: 1569-1582
  10. ↑ , 11. Laufs U, Custodis F, Böhm M (2006). “HMG-CoA Reductase Inhibitors in Chronic Heart Failure”. Drugs, 66: 145
  11. ↑ Porter, K.E.; Turner, N.A.; Statins and myocardial remodeling: cell and molecular pathways; expert reviews in molecular medicine, 2011, 13 (22): pp.1-18
  12. ↑ , Miettinen TA (1982). “Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins”. The Journal of Lipid Research, 23: 466-473
  13. ↑ , Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M (1996). “Metabolism of cerivastatin by human liver microsomes in vitro”. Drug Metabolism and Dispersion, 25 (3): 321-331
  14. 1 2 Kalaria, D.; Wassenaar, W.; “Rhabdomyolysis and cerivastatin: Was it a problem of dose?” CMAJ, 167 (7), 2002, p. 737
  15. ↑ Moßhammer, D.; Schaeffeler, E.; Schwab, M.; Mörike, K.; Mechanisms and assessment of statin-related muscular adverse effects. British Journal of Clinical Pharmacology, 78(3), 2014, pp. 454–466
  16. ↑ [do:10.1001/jama.292.21.2622. PMID 15572720], Psaty BM, Furberg CD, Ray WA, Weiss NS (2004). "Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". JAMA. 292 (21): 2622–31
  17. 1 2 3 Staffa JA, Chang J, Green L (2002). “Cerivastatin and Reports of Fatal Rhabdomyolysis”. N Engl J Med, 346: 539-540
  18. 1 2 [doi:10.1001/jama.292.21.2622. PMID 15572720.], Psaty BM, Furberg CD, Ray WA, Weiss NS (2004). "Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". JAMA. 292 (21): 2622–31
  19. ↑ Furberg CD, Pitt B (2001). “Withdrawal of cerivastatin from the world market”. Curr Control Trials Cardiovasc Med, 2 (5): 205-207
  20. ↑ , 15. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M (1996). “Metabolism of cerivastatin by human liver microsomes in vitro”. Drug Metabolism and Dispersion, 25 (3): 321-331